2017

1. Desportes, E., Wagner, M., Kamal, M., Salomon, A.V., Deniziaut, G., Pierron, G., Rouleau, E., Jouffroy, T., **Le Tourneau, C.**, Paoletti, X., and Servois, V. Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial. Oncotarget. (2017).
2. **Le Tourneau, C.**, Kamal, M., and Bièche, I. The SHIVA01 trial: what have we learned? Pharmacogenomics. (2017).

2016

1. Amirouchene-Angelozzi, N., Frisch-Dit-Leitz, E., Carita, G., Dahmani, A., Raymondie, C., Liot, G., Gentien, D., Némati, F., **Decaudin, D.**, Roman Roman, S., and **Schoumacher, M.** The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma. Oncotarget. (2016).
1. Belin, L., Kamal, M., Mauborgne, C., Plancher, C., Mulot, F., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Ricci, F., Alt, M., **Loirat, D.**, Sablin, M.-P., Paoletti, X., Servois, V., and **Le Tourneau, C..** Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Cross-over analysis from the SHIVA trial. Ann. Oncol. (2016).
2. Carita, G., Frisch-Dit-Leitz, E., Dahmani, A., Raymondie, C., Cassoux, N., Piperno-Neumann, S., Némati, F., **Laurent, C.**, De Koning, L., Halilovic, E., Jeay, S., Wylie, A., Emery, C., Roman Roman, S., **Schoumacher, M.**, and **Decaudin, D.** Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. Oncotarget. (2016).
3. **Decaudin, D.**, and **Le Tourneau, C.** Combinations of targeted therapies in human cancers. Aging (Albany NY). (2016).
4. der Houven van Oordt, C.W.M., Gomez-Roca, C., Herpen, C. van, Coveler, A.L., Mahalingam, D., Verheul, H.M.W., van der Graaf, W.T.A., Christen, R., Rüttinger, D., Weigand, S., Cannarile, M.A., Heil, F., Brewster, M., Walz, A.-C., Nayak, T.K., Guarin, E., Meresse, V., and **Le Tourneau, C.** First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget. (2016).
5. **Han, Z.-Y**., **Richer, W.**, Fréneaux, P., **Chauvin, C.**, Lucchesi, C., Guillemot, D., Grison, C., Lequin, D., Pierron, G., Masliah-Planchon, J., **Nicolas, A.**, Ranchère-Vince, D., Varlet, P., Puget, S., Janoueix-Lerosey, I., Ayrault, O., **Surdez, D.**, Delattre, O., and **Bourdeaut, F.** The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation. Nat Commun. (2016).
6. **Le Tourneau, C.**, and Kurzrock, R. Targeted therapies: What have we learned from SHIVA? Nat Rev Clin Oncol. (2016).
7. **Le Tourneau, C.**, Kamal, M., Tsimberidou, A.-M., Bedard, P., Pierron, G., Callens, C., Rouleau, E., Vincent-Salomon, A., Servant, N., Alt, M., Rouzier, R., Paoletti, X., Delattre, O., and Bièche, I. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. J. Natl. Cancer Inst. (2016).
8. Sablin, M.-P., Dubot, C., Klijanienko, J., Vacher, S., Ouafi, L., Chemlali, W., Caly, M., Sastre-Garau, X., Lappartient, E., Mariani, O., Rodriguez, J., Jouffroy, T., Girod, A., Calugaru, V., Hoffmann, C., Lidereau, R., Berger, F., Kamal, M., Bieche, I., and **Le Tourneau, C.** Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas. Oncotarget. (2016).
9. Tury, S., Becette, V., Assayag, F., Vacher, S., Benoist, C., Kamal, M., Marangoni, E., Bièche, I., Lerebours, F., and Callens, C. Combination of COX-2 expression and

Authors funded by SIRIC are in bold. Underlined authors are program and project coordinators.

PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer. Oncotarget. (2016).

2015

1. Doussau, A., Thiébaut, R., Geoerger, B., Schöffski, P., Floquet, A., Deley, M.C.L., Mathoulin-Pélissier, S., Rizzo, E., Fumoleau, P., **Le Tourneau, C.**, and Paoletti, X. A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials. Ann. Oncol. (2015).
2. **Ezzalfani, M.**, Dugué, A., Mollevi, C., Pulido, M., Bonnetain, F., Filleron, T., Gal, J., Gauthier, M., Deley, M.C.L., **Le Tourneau, C..**, Médioni, J., Nguyen, J.-M., Chabaud, S., Teixeira, L., Thivat, E., You, B., Kramar, A., and Paoletti, X. [The role of the expansion cohort in phase I trials in oncology: Guidelines of the phase I HUB.]. Bull Cancer. (2015).
3. **Le Tourneau, C.**, Belin, L., Paoletti, X., Bièche, I., and Kamal, M. Precision medicine: lessons learned from the SHIVA trial - Authors' reply. Lancet Oncol. (2015).
4. **Le Tourneau, C..**, Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., Armanet, S., Servant, N., Bièche, I., **Bernard, V.**, Gentien, D., Jezequel, P., Attignon, V., Boyault, S., Vincent-Salomon, A., Servois, V., Sablin, M.-P., Kamal, M., Paoletti, X., and SHIVA investigators Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. (2015).
5. Marous, M., Bièche, I., Paoletti, X., Alt, M., Razak, A.R.A., Stathis, A., Kamal, M., and **Le Tourneau, C.** Designs of preoperative biomarkers trials in oncology: a systematic review of the literature. Ann. Oncol. (2015).
6. Paoletti, X., Asselain, B., Kamal, M., Servant, N., Huppé, P., Bieche, I., and **Le Tourneau, C.** Design and statistical principles of the SHIVA trial. Chin Clin Oncol. (2015).
7. Paoletti, X., **Ezzalfani, M.**, and **Le Tourneau, C..** Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Ann. Oncol. (2015).
8. Paoletti, Xavier, Doussau, A., **Ezzalfani, M.**, Rizzo, E., and Thiébaut, R. Dose finding with longitudinal data: simpler models, richer outcomes. Statist. Med. (2015).
9. Riviere, M.-K., **Le Tourneau, C.**, Paoletti, X., Dubois, F., and Zohar, S. Designs of drug-combination phase I trials in oncology: a systematic review of the literature. Ann. Oncol. (2015).

2014

1. Boeva, V., Popova, T., Lienard, M., Toffoli, S., Kamal, M., **Le Tourneau, C..**, Gentien, D., Servant, N., Gestraud, P., Rio Frio, T., Hupé, P., Barillot, E., and Laes, J.-F. Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. Bioinformatics. (2014).
2. Chanrion, M., Kuperstein, I., Barrière, C., Marjou, F.E., Cohen, D., Vignjevic, D., Stimmer, L., Paul-Gilloteaux, P., Bièche, I., Tavares, S.D.R., Boccia, G.-F., Cacheux, W., **Meseure, D.**, Fre, S., Martignetti, L., Legoix-Né, P., Girard, E., Fetler, L., Barillot, E., Louvard, D., Zinovyev, A., and Robine, S. Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Nature Communications. (2014).
3. **Le Tourneau, C.**, Paoletti, X., Coquan, E., Sablin, M.-P., Zoubir, M., and Tannock, I.F. Critical Evaluation of Disease Stabilization As a Measure of Activity of Systemic Therapy: Lessons From Trials With Arms in Which Patients Do Not Receive Active Treatment. J. Clin. Oncol. (2014).

4. **Le Tourneau, C.**, <u>Paoletti, X.</u>, Servant, N., Bièche, I., Gentien, D., Rio Frio, T., <u>Vincent-Salomon, A.</u>, <u>Servois, V.</u>, **Romejon, J.**, Mariani, O., **Bernard, V.**, Huppe, P., Pierron, G., Mulot, F., Callens, C., Wong, J., Mauborgne, C., Rouleau, E., Reyes, C., Henry, E., Leroy, Q., Gestraud, P., La Rosa, P., Escalup, L., Mitry, E., Trédan, O., Delord, J.-P., Campone, M., Goncalves, A., Isambert, N., Gavoille, C., and <u>Kamal, M.</u> Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. British Journal of Cancer. (2014).

5. **Le Tourneau, C..**, <u>Kamal, M.</u>, Alt, M., Verlingue, L., <u>Servois, V.</u>, Sablin, M.-P., Servant, N., and <u>Paoletti, X.</u> The spectrum of clinical trials aiming at personalizing medicine. Chin Clin Oncol. (2014).

6. <u>Paoletti, X.</u>, **Le Tourneau, C.**, Verweij, J., Siu, L.L., Seymour, L., Postel-Vinay, S., Collette, L., Rizzo, E., Ivy, P., Olmos, D., Massard, C., Lacombe, D., Kaye, S.B., and Soria, J.-C. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. Eur. J. Cancer. (2014).

7. Postel-Vinay, S., Collette, L., <u>Paoletti, X.</u>, Rizzo, E., Massard, C., Olmos, D., Fowst, C., Levy, B., Mancini, P., Lacombe, D., Ivy, P., Seymour, L., **Le Tourneau, C.**, Siu, L.L., Kaye, S.B., Verweij, J., and Soria, J.-C. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. Eur. J. Cancer. (2014).

8. Servant, N., **Roméjon, J.**, Gestraud, P., La Rosa, P., Lucotte, G., Lair, S., **Bernard, V.**, Zeitouni, B., Coffin, F., Jules-Clément, G., Yvon, F., Lermine, A., Poullet, P., Liva, S., Pook, S., Popova, T., Barette, C., Prud'homme, F., Dick, J.-G., <u>Kamal, M.</u>, **Le Tourneau, C.**, <u>Barillot, E.</u>, and Hupé, P. Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial. Front Genet. (2014).

2013

1. Doussau, A., Thiébaut, R., and <u>Paoletti, X.</u> Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials. Statistics in Medicine. (2013).

2. <u>Paoletti, X.</u>, Geoerger, B., <u>Doz, F.</u>, Baruchel, A., Lokiec, F., and **Le Tourneau, C.** A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials. Eur. J. Cancer. (2013).

2012

1. Doussau, A., Asselain, B., Le Deley, M.C., Geoerger, B., <u>Doz, F.</u>, Vassal, G., and <u>Paoletti, X.</u> Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline framework. Contemp Clin Trials. (2012).

2. **Le Tourneau, C.**, Gan, H.K., Razak, A.R.A., and <u>Paoletti, X.</u> Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents. PLoS ONE. (2012).

3. **Le Tourneau, C.**, <u>Kamal, M.</u>, Trédan, O., Delord, J.-P., Campone, M., Goncalves, A., Isambert, N., Conroy, T., Gentien, D., <u>Vincent-Salomon, A.</u>, Pouliquen, A.-L., Servant, N., <u>Stern, M.-H.</u>, Le Corroller, A.-G., Armanet, S., Rio Frio, T., and <u>Paoletti, X.</u> Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Targeted Oncology. (2012).

4. **Le Tourneau, C.**, <u>Servois, V.</u>, <u>Diéras, V.</u>, Ollivier, L., Tresca, P., and <u>Paoletti, X.</u> Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. Br. J. Cancer. (2012).